Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL
Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome
Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis
Exploring genomic insights in acute lymphoblastic leukaemia treatment
Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years
Essential breast cancer medicines
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma